Loading...
Loading...
ADMA| Name | Value |
|---|---|
| Revenues | 107.2M |
| Cost of Revenue | 49.9M |
| Gross Profit | 57.3M |
| Operating Expense | 18.1M |
| Operating I/L | 39.2M |
| Other Income/Expense | -3.4M |
| Interest Income | 0.4M |
| Pretax | 35.9M |
| Income Tax Expense | 3.8M |
| Net Income/Loss | 32.1M |
ADMA Biologics, Inc. is a biopharmaceutical company specializing in the development, manufacturing, and marketing of plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. The company's product portfolio includes BIVIGAM and ASCENIV, intravenous immune globulin (IVIG) products for primary humoral immunodeficiency (PI) treatment, as well as Nabi-HB for Hepatitis B exposure. ADMA Biologics also focuses on developing a pipeline of plasma-derived therapeutics, particularly related to S. pneumonia infection prevention. The company generates revenue by selling its products through independent distributors, sales agents, specialty pharmacies, and alternate site providers.
